SCHEMBL20607402

SCHEMBL20607402

Cc1cc(C=O)c(OCc2ccccc2)c(Cl)c1OCc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.43
MRGPRX4 Q96LA9 2/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
MCL1 Q07820 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
HPGD P15428 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HTT P42858 1/20 0.41
LMNA P02545 3/20 0.40
GAA P10253 1/20 0.40
GLRA1 P23415 1/20 0.40
PTPN1 P18031 1/20 0.40
ERN1 O75460 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CCNB2 O95067 1/20 0.39
CDK1 P06493 1/20 0.39
CDK4 P11802 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20607133 0.92 LMNA (0.39) POLBMRGPRX4MAOAMAOBMCL1
SCHEMBL20607047 0.88 ERN1 (0.48) POLBMRGPRX4MAOAMAOBMCL1
SCHEMBL28743394 0.86 MRGPRX4 (0.51) POLBMRGPRX4MAOAMAOBMEN1
SCHEMBL25877949 0.82 PTPN1 (0.45) POLBMAOAMAOBMEN1KMT2A
SCHEMBL25817126 0.82 PTPN1 (0.45) POLBMAOAMAOBMEN1KMT2A
SCHEMBL28743422 0.80 LMNA (0.48) POLBMRGPRX4MAOAMAOBMEN1
SCHEMBL20607246 0.80 LMNA (0.46) POLBMRGPRX4MAOAMAOBMEN1
SCHEMBL25877421 0.80 MAOA (0.42) POLBMAOAMAOBMEN1KMT2A
SCHEMBL25877526 0.79 PTPN1 (0.48) POLBMAOAMAOBMEN1KMT2A
SCHEMBL22067805 0.79 ERN1 (0.50) POLBMAOAMAOBHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400520-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-12-05 US disclosed
CN-108779076-B 5-methyl-6-phenyl-4, 5-dihydro-2H-pyridazin-3-one derivatives 大塚制药株式会社 2022-05-03 CN disclosed
EP-3423440-B9 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE FOR THE TREATMENT OF BRAIN TUMORS OTSUKA PHARMA CO LTD (JP) 2021-07-28 EP disclosed
US-20210171472-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-06-10 US disclosed
US-20210171472-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-06-10 US disclosed
EP-3423440-B1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE FOR THE TREATMENT OF BRAIN TUMORS OTSUKA PHARMA CO LTD (JP) 2021-01-06 EP disclosed
US-20200181092-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-06-11 US disclosed
US-20200181092-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-06-11 US disclosed
US-10611731-B2 5-methyl-6-phenyl-4,5-dihydro-2H-pyridazin-3-one derivative OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-07 US disclosed
US-10611731-B2 5-methyl-6-phenyl-4,5-dihydro-2H-pyridazin-3-one derivative OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-07 US disclosed
US-20190023662-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-01-24 US disclosed
US-20190023662-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-01-24 US disclosed
EP-3423440-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE Otsuka Pharmaceutical Co., Ltd. (JP) 2019-01-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171472-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE VHL, H1-5, PRMT5 POLB 3038/4885MRGPRX4 479/4885MAOA 2536/4885
US-20200181092-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE VHL, H1-5, PRMT5 POLB 3038/4885MRGPRX4 479/4885MAOA 2536/4885
US-20240400520-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE VHL, H1-5, PRMT5 POLB 3038/4885MRGPRX4 479/4885MAOA 2536/4885
US-20190023662-A1 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE VHL, H1-5, PRMT5 POLB 3038/4885MRGPRX4 479/4885MAOA 2536/4885
US-10611731-B2 5-methyl-6-phenyl-4,5-dihydro-2H-pyridazin-3-one derivative VHL, H1-5, PRMT5 POLB 3038/4885MRGPRX4 479/4885MAOA 2536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.